(Q38075029)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

Emerging drugs for managing kidney disease in patients with diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Merlin C Thomas

series ordinal

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

21 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

55-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

Economic costs of diabetes in the US in 2002.

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The incidence and implications of aldosterone breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Expanding targets of vitamin D receptor activation: downregulation of several RAS components in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The expanding spectrum of biological actions of vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Potential for vitamin D receptor agonists in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Renoprotective role of the vitamin D receptor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The impact of diabetes mellitus on vitamin D metabolism in predialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Meta-analysis: the effect of statins on albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Physiological role of ROCKs in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Rho kinases in cardiovascular physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The potential role of thiamine (vitamin B1) in diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Pyridorin in type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Activation of tubular epithelial cells in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

A glimpse of various pathogenetic mechanisms of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1alpha expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The role of tubular epithelial-mesenchymal transition in progressive kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Connective tissue growth factor: just another factor in renal fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The time has come to target connective tissue growth factor in diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

What is the role of decorin in diabetic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

The effect of ruboxistaurin on nephropathy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Oxidative stress as a major culprit in kidney disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of NADPH oxidase inhibitor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effect of combination therapy with dipyridamole and quinapril in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Role of endothelin and endothelin receptor antagonists in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Effects of endothelin receptor antagonists on the progression of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Antidiuretic effects of the endothelin receptor antagonist avosentan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

Involvement of Connective Tissue Growth Factor in Human and Experimental Hypertensive Nephrosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.762356

10.1517/14728214.2013.762356

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23330907%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference